Bloomberg Markets with Carol Massar and Cory Johnson.

GUEST:
David Nierengarten
Head of Health Care Equity Research 
Wedbush Securities 
Discussing investing in biotech stocks, inlcuding Blueprint Medicines.

<p>Bloomberg Markets with Carol Massar and Cory Johnson.

GUEST:
David Nierengarten
Head of Health Care Equity Research 
Wedbush Securities 
Discussing investing in biotech stocks, inlcuding Blueprint Medicines.</p>

Listen for reporting from the magazine that helps global leaders stay ahead. Hosts Carol Massar and Tim Stenovec cover the changing world of money, power and technology. You can watch and listen to Businessweek LIVE on YouTube, weekdays from 2PM to 5PM ET: http://bit.ly/3vTiACF. 

<p>Listen for reporting from the magazine that helps global leaders stay ahead. Hosts Carol Massar and Tim Stenovec cover the changing world of money, power and technology.&nbsp;You can watch and listen to Businessweek LIVE on YouTube, weekdays from 2PM to 5PM ET:&nbsp;<a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.&nbsp;</p>

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more by harnessing the power of Bloomberg Businessweek reporters and editors.

Bloomberg Businessweek

Bloomberg Markets: Nierengarten on Small, Mid-Market Biotech

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/17660afe-5ef8-4263-a64a-ae2b00f65458/transcript